ASBMB journals will be fully open access in 2021
Earlier today, the American Society for Biochemistry and Molecular Biology announced that its three peer-reviewed journals will become, as of January, open access. You can read the announcement in full below. The society also created a page with frequently asked questions.
As elected, editorial and administrative leaders of the American Society for Biochemistry and Molecular Biology, we are pleased to announce that the society’s three highly regarded journals — Journal of Biological Chemistry, Molecular & Cellular Proteomics and Journal of Lipid Research — will be fully open access beginning in January 2021.
The ASBMB exists to meet the needs and respond to the demands of its members, and our members, in line with the broader scientific community, have called for immediate and free public access to research published in ASBMB journals in order to reduce barriers to scientific knowledge and accelerate discoveries.
ASBMB journals have for years made accepted manuscripts immediately available for free as Papers in Press and have embargoed the final redacted versions of articles for subscribers for only a single year. In addition, authors have had the option to pay an additional fee for immediate open access of the final version of a paper or upload the accepted version for free to a public repository. As of January, the final versions of all articles will be immediately available to everyone, qualifying ASBMB journals as “gold” open access. This is important because an increasing number of funders of biomedical research are requiring its grantees to publish in only “gold” journals.
Our decision-making process was careful and consultative. During our months-long deliberations, we had to balance what is best for science and scientists with what is sustainable for a nonprofit organization. Ultimately, we determined that the ASBMB cannot achieve its goal of full open access alone, so we made the strategic decision to enter into an agreement with the commercial publisher Elsevier, which has experience transitioning subscription journals to full open access and the requisite technical expertise and infrastructure.
We want to emphasize that this agreement will not change the peer-review process at any of our journals. JBC, MCP and JLR remain committed to rigorous, fast and fair review — by active scientists.
We are happy to report, also, that the agreement will smooth the submission process for authors and reduce the cost of open-access publishing — for both members and nonmembers alike. It also will make our journals easier to read on mobile devices, discoverable on the platform ScienceDirect and, generally speaking, more nimble technologically.
Transitioning from a subscription model to an open-access model is complicated, but we know this is the right decision for the ASBMB. Throughout our deliberations, we kept focused on our goal: to make the high-quality papers we publish immediately and permanently available for everyone to read, download, copy and distribute.
We will share more information on the transition in the months to come. In the meantime, we hope that you will reach out to us if you have any questions or concerns.
Sincerely,
Gerald Hart (President, ASBMB)
Joan Conaway (Treasurer, ASBMB)
Sandra Weller (Chair, ASBMB Publications Committee)
Toni Antalis (President-elect, ASBMB)
Lila M. Gierasch (Editor-in-Chief, Journal of Biological Chemistry)
Alma Burlingame (Editor-in-Chief, Molecular & Cellular Proteomics)
Kerry-Anne Rye and Nicholas O. Davidson (Co-Editors, Journal of Lipid Research)
Barbara Gordon (Executive Director, ASBMB)
Nancy Rodnan (Senior Director, ASBMB Publications)
Steve Miller (Deputy Executive Director and Chief Financial Officer, ASBMB)
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Blood proteomics reveals fungal infection signatures for faster diagnosis
Whole-blood proteomics identifies more than 3,000 host and 160 fungal proteins during cryptococcal infection, offering potential biomarkers for faster diagnosis and improved monitoring without invasive spinal taps.

When things get SAPpy: Novel insights into complement
Researchers have defined interactions between an innate immune protein and two of its known binding partners. They identified potential areas of crosstalk between the two binding interactions.

Glutathione pathway implicated in rare disease
Researchers found that glutathione metabolism plays a central role in the pathogenesis of rare disease methylmalonic aciduria using a novel multiomics approach.

A p-value for proteins
Kyoto University researchers developed UniScore, a new tool that uses a target-decoy method to filter false positives in proteomic searches, helping scientists set thresholds and improve reliability when analyzing complex protein data.

Novel way to uncover tumor microenvironment proteomics
Researchers at the Weizmann Institute of Science developed a novel single-cell approach that facilitates the study of proteins surrounding lung cancer cells.

Sizing up cells: How stem cells know when to divide
Stanford University researchers find that stem cells control their size early in cell division across living multicellular systems.